100 related articles for article (PubMed ID: 8066629)
1. Adverse effects of OKT3 therapy: increased risk with impaired renal function.
Kehinde EO; Scriven SD; Feehally J; Veitch PS; Varty K; Bell PR
Transplant Proc; 1994 Aug; 26(4):1945-7. PubMed ID: 8066629
[No Abstract] [Full Text] [Related]
2. Cardiovascular effects of ATG and OKT3 in renal allograft recipients.
Spieker C; Barenbrock M; Buchholz B; Heidenreich S; Zidek W
Transplant Proc; 1992 Dec; 24(6):2594-5. PubMed ID: 1465876
[No Abstract] [Full Text] [Related]
3. Low-dose OKT3 induction therapy following renal transplantation leads to improved graft function and decreased adverse effects.
Brown M; Korb S; Light JA; Light T; Jonsson J; Aquino A
Transplant Proc; 1993 Feb; 25(1 Pt 1):553-5. PubMed ID: 8438411
[No Abstract] [Full Text] [Related]
4. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
[TBL] [Abstract][Full Text] [Related]
5. Clinical and renal histologic predictors of long-term outcome after OKT3 therapy for steroid-resistant rejection.
Wiener Y; Nakhleh RE; Kupin WL; Lee M; Escobar FS; Venkat KK; Mozes MF
Transplant Proc; 1995 Feb; 27(1):1014-5. PubMed ID: 7878781
[No Abstract] [Full Text] [Related]
6. Cytomegalovirus infection during OKT3 treatment for renal allograft rejection.
Morgan JD; Horsburgh T; Simpson A; Donnelly PK; Veitch PS; Bell PR
Transplant Proc; 1992 Dec; 24(6):2634-5. PubMed ID: 1334589
[No Abstract] [Full Text] [Related]
7. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
[No Abstract] [Full Text] [Related]
8. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
9. Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection.
Jeffrey RF; Johnson MH; Bamford JM; Giles GR; Brownjohn AM; Will EJ
Transplantation; 1993 Mar; 55(3):677-9. PubMed ID: 8456493
[No Abstract] [Full Text] [Related]
10. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity.
Vasquez EM; Fabrega AJ; Pollak R
Transplant Proc; 1995 Feb; 27(1):873-4. PubMed ID: 7879215
[No Abstract] [Full Text] [Related]
11. The treatment of steroid-resistant renal allograft rejection with OKT3 and plasmapheresis.
Haberal M; Sert S; Gülay H; Arslan G; Bilgin N
Transplant Proc; 1990 Aug; 22(4):1761-3. PubMed ID: 2117801
[No Abstract] [Full Text] [Related]
12. Role of cyclosporine rescue therapy in steroid resistant rejections.
Sharma RK; Elhence R; Kher V; Gupta A; Kumar A; Bhandari M; Agrawal S
Transplant Proc; 1994 Oct; 26(5):2556-7. PubMed ID: 7940789
[No Abstract] [Full Text] [Related]
13. OKT3 for the treatment of steroid-resistant acute renal allograft rejection.
Jogose JT; Bailey RR; Lynn KL; Robson RA; Wells JE
Nephron; 1997; 77(3):298-303. PubMed ID: 9375823
[TBL] [Abstract][Full Text] [Related]
14. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield CF
Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
[No Abstract] [Full Text] [Related]
15. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
VanderWerf BA
Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172
[No Abstract] [Full Text] [Related]
16. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
van Son WJ; van den Berg AP; The TH; Tegzess AM
Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
[No Abstract] [Full Text] [Related]
17. Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1993 Aug; 25(4):2574. PubMed ID: 8356675
[No Abstract] [Full Text] [Related]
18. [Differential diagnosis of transplant function disorders in therapy with monoclonal antibodies OKT3].
Müller T; Keuchel M; Schindler S; Steinmetz A; Feiber H; Lange H
Helv Chir Acta; 1991 Sep; 58(3):271-5. PubMed ID: 1769844
[TBL] [Abstract][Full Text] [Related]
19. Low-dose OKT3 for cadaveric renal transplantation.
Schweizer RT; Roper L; Hull D; Bartus SA
Transplant Proc; 1992 Dec; 24(6):2592-3. PubMed ID: 1465875
[No Abstract] [Full Text] [Related]
20. OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).
First MR; Schroeder TJ; Hariharan S
Transplant Proc; 1993 Apr; 25(2 Suppl 1):25-6. PubMed ID: 8465417
[No Abstract] [Full Text] [Related]
[Next] [New Search]